Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO) News
Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO)
Today's Latest Price: $58.63 USD
Updated Oct 30 7:00pm
Add TARO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
Filter TARO News Items
TARO News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TARO News From Around the Web
Below are the latest news stories about Taro Pharmaceutical Industries Ltd that investors may wish to consider to help them evaluate TARO as an investment opportunity.
Taro Pharmaceutical launches generic Deferiprone in U.S.Taro Pharmaceutical ([[TARO]] -0.5%) has announced the launch of deferiprone, a generic version of Chiesi's Ferriprox, an iron chelator indicated for transfusional iron overload due to thalassemia syndromes, when current chelation therapy is not sufficient.The company will team up with BioPlus Specialty Pharmacy for distribution of deferiprone tablets at launch.... |
Legal woes, decline in sales hurt Sun Pharma: Q1 key takeawaysNEW DELHI: Hurt by one-time loss, leading drugmaker Sun Pharma reported a surprising loss during the June quarter while sales declined in all regions of the world the company operates in.However, the management hailed the company's performance. They said it has done well given the challenges it faced and managed to hold its market share in India and the US.How much did the company earn?Sun Pharma reported a loss of Rs 1,655.60 crore in the quarter, sharply lower from the expectation as it recognised an exceptional item. The company’s revenues from operations also fell to Rs 7,467.19 crore, from Rs 8,259.30 crore a year ago. EBITDA was at Rs 1,725 crores, with resulting EBITDA margin of 23.1 per cent.What is that exceptional item?The company reported a one-time loss of Rs 3,633.33 crore ... |
Sun Pharma's Subsidiary Taro Pharma To Acquire Canada's Aquinox PharmaOn Wednesday, in a stock exchange filing, Sun Pharma said that a subsidiary of its American arm Taro Pharmaceutical will acquire Canada's Aquinox Pharmaceutical for $8.2 million (approx Rs 61.35 crore) in cash. Aquinox Pharmaceuticals is a corporation organised |
Taro Pharma to acquire Canada’s Aquinox Pharmaceutical for USD 8.2 million | BusinessDrug major Sun Pharma on Wednesday said a subsidiary of its American arm Taro Pharmaceutical will acquire Canada's Aquinox Pharmaceutical for USD 8.2 million (approx Rs 61.35 crore) in cash. 100 per cent shareholding, constituting equity shares and non-voting preferred shares, will be acquired, it said. A cash consideration of USD 8.2 million will be paid for acquisition of all shares of Aquinox Pharmaceutical, Sun Pharma said. |
Sun Pharma to acquire Canada's Aquinox PharmaceuticalsSun Pharmaceutical Industries on Wednesday said that a wholly-owned subsidiary of Taro Pharmaceutical Industries Ltd will acquire Aquinox Pharmaceuticals (Canada) Inc for $8.2 million. |
Sun Pharma to acquire Canada-based Aquinox Pharmaceuticals for $8.2mSun Pharmaceutical Industries has announced that one of the fully-owned subsidiaries of Taro Pharmaceutical Industries Ltd is about to to acquire Aquinox Pharmaceuticals (Canada) Inc for $8.2 milli… |
Sun Pharma Gains As US Subsidiary Achieves Resolution On Antitrust InvestigationsOn Friday, shares of Sun Pharmaceutical Industries Limited rose 4 percent to Rs 497.80 in early trade after its US subsidiary, Taro Pharma reached a settlement agreement with the US Department of Justice (DoJ), Antitrust and Civil divisions to pay $205.7 |
Sun Pharma's arm Taro resolves all cases with United States Department of JusticeNew Delhi: Sun Pharma on Friday said its American arm Taro Pharmaceutical has resolved all cases involving multi-year investigations by US Department of Justice into the country's generic pharmaceutical industry. The US Department of Justice (DOJ) had launched investigations against the company over generic drug pricing. "Taro Pharmaceuticals USA, Inc, has resolved all cases involving the company in connection with the multi-year investigations by the DOJ, Antitrust Division and Civil Division, into the US generic pharmaceutical industry," Sun Pharma said in a regulatory filing. Under a deferred prosecution agreement reached with the DOJ, it said, adding that the department will file an information for conduct that took place between 2013 and 2015. Taro Pharmaceutical said, if the compa... |
Taro Pharma settles U.S. price-fixing chargesTaro Pharmaceuticals (TARO) says it agrees to pay ~$205M to settle allegations by the Department of Justice that it conspired to fix prices and rig bids for generic drugs.Under the terms of a three-year deferred prosecution agreement, Taro also agrees to cooperate in the DoJ's ongoing investigation.Taro and other companies... |
Taro Achieves Global Resolution of DOJ Antitrust InvestigationsTaro Achieves Global Resolution of DOJ Antitrust Investigations |
